CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
ABT-267 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01563536
NCT01563536Phase 2Completed
CompareCT.gov

An Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

AbbVie (prior sponsor, Abbott)·interventional·Posted Mar 27, 2012·Updated Jul 2, 2018

In Brief

A Phase 2 clinical trial evaluating ABT-267, ABT-450, and 3 other interventions for Chronic Hepatitis C Infection. Completed, enrolled 12 participants across 4 sites.

Detailed Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and antiviral activity of multiple, ascending doses of ABT-267 (also known as ombitasvir) administered as two-day monotherapy followed by ABT-267 in combination therapy with other direct-acting antiviral agents (DAAs) ABT-450 with ritonavir (ABT-450/r) and ABT-333 (also known as dasabuvir) plus ribavirin (RBV) in patients with chronic Hepatitis C virus (HCV) infection without cirrhosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Infection
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 27, 2012
Enrollment StartFeb 1, 2012
Primary CompletionApr 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.3 years ago

Interventions

ABT-267drug

Tablet

ABT-450drug

Tablet

ABT-333drug

Tablet

Ritonavirdrug

Capsule

Ribavirindrug

Tablet